News

Swedish firm Dilaforette has received orphan drug designation from the US Food and Drug Administration (FDA) for its sevuparin (DF02) to treat patients with sickle-cell disease (SCD). With an aim to start recruitment of patients during...

Germany-based Evotec has signed an agreement with French drugmaker Sanofi for a major multi-component strategic partnership over the next five years. As part of the deal, Sanofi will provide around €250m to Evotec, including more than...

US-based Eli Lilly and Company has signed an exclusive licence and collaboration agreement with Hanmi Pharmaceutical to develop and commercialise an immunological therapy. Under the deal, both firms will develop Hanmi's oral Bruton's tyrosine kinase (BTK)...

Researchers at London's Institute of Cancer Research (ICR) have found that cancer cells with a fault in the protein-coding CBLC gene could be sensitive to the poly ADP-ribose polymerase (PARP) inhibitor drugs. Approved in December last...

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in children aged between two and five years. The approval allows the drug to...

Actavis has completed the acquisition of US-based Botox-maker Allergan, in a deal valued around $70.5bn. With combined annual pro forma revenues of about $23bn expected this year, the combination is said to create one of the...

INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the...